PharmaShots | Incisive News in 3 Shots

Subscribe Now

rare blood disorder

Celgene's Reblozyl (luspatercept–aamt) Receives FDA's Approval as the First Therapy to Treat Patients with Rare Blood Disorder

Celgene's Reblozyl (luspatercept–aamt) Receives FDA's Approval as the First Therapy to Treat Patients with Rare Blood Disorder

November 11, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us